Neutral
Here’s Insiders Fund’s Thesis on Insulet Corporation (PODD)
Alpha Wealth Funds, LLC's "Insiders Fund" discussed Insulet Corporation (NASDAQ:PODD) in its Q1 2026 investor letter. While the fund acknowledged PODD...
PODD
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (7)
Neutral (10)
Bearish (1)
Latest PODD News
Neutral
Bullish
William Blair initiates Insulet stock coverage with Outperform rating By Investing.com
William Blair has initiated coverage on Insulet Corporation (NASDAQ:PODD) with an Outperform rating, noting the stock is undervalued compared to peers...
Bullish
William Blair Assumes Insulet Corporation (PODD) at Outperform
William Blair analyst Steve Lichtman initiated coverage on Insulet Corporation (PODD) with an Outperform rating. The article, however, is premium cont...
Neutral
What Insulet (PODD)'s Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders
Insulet Corporation recently reported strong Q1 results with $761.7 million in revenue and $91.1 million in net income, confirmed upgraded 2026 revenu...
Neutral
Insulet stock (US45784P1012): 52-week low after strong quarterly growth raises questions for investo
Insulet's stock recently hit a new 52-week low despite the company reporting strong Q4 2025 revenue and earnings growth, driven by its Omnipod insulin...
Neutral
Some May Be Optimistic About Insulet's (NASDAQ:PODD) Earnings
Insulet Corporation's recent earnings report was disappointing due to soft headline numbers, but the article suggests that investors might be overlook...
Bullish
Benchmark Initiates Insulet at Buy With $250 Price Target
Benchmark has initiated coverage of Insulet Corporation (PODD) with a "Buy" rating and set a price target of $250. This news follows a series of recen...
Bullish
Insulet establishes Middle East regional headquarters in Riyadh, marking a strategic milestone in the Kingdom
Insulet Corporation, a global leader in tubeless insulin pump technology, has opened its Middle East and North Africa regional headquarters in Riyadh,...
Bullish
Insulet stock (US45784P1012): Q4 2025 revenue beats estimates with 31% growth
Insulet (PODD) reported strong Q4 2025 results with revenue of $783.8 million, a 31.2% year-over-year increase, surpassing Wall Street estimates by 2%...
Neutral
Insulet (PODD) Is Down 6.8% After Raising 2026 Guidance And Advancing Closed‑Loop Trial - What's Changed
Insulet (PODD) recently reported strong first-quarter 2026 results, with revenue rising to US$761.7 million and net income of US$91.1 million. The com...
Bullish
Insulet Corp (PODD) Shares Fall 3.8% -- What GF Score of 83 Tells Investors
Insulet Corp (PODD) shares dropped 3.8% to $154.11, adding to a significant year-to-date decline of 45.8%. Despite the fall, the company holds a stron...
Neutral
Insulet Corporation (PODD) PT Lowered to $200 at Bernstein SocGen Group, 'shares fall; what now?'
Bernstein SocGen Group analyst Lee Hambright lowered the price target for Insulet Corporation (PODD) to $200 from $330, while maintaining an Outperfor...
Neutral
Earnings To Watch: Insulet (PODD) Reports Q1 Results Tomorrow
Insulet Corporation (PODD), an insulin delivery company, is scheduled to report its Q1 earnings this Wednesday. The market anticipates a 28.4% year-on...
Neutral
Insulet begins pivotal trial for fully closed-loop diabetes system
Insulet Corporation has started a pivotal clinical trial, EVOLVE, for its fully closed-loop automated insulin delivery system aimed at type 2 diabetes...
Bullish
Insulet begins study of insulin system that removes mealtime dosing
Insulet Corporation has enrolled the first patient in its pivotal EVOLVE study, evaluating a new fully closed-loop automated insulin delivery (AID) sy...
Neutral
Comerica Bank Sells 17,712 Shares of Insulet Corporation $PODD
Comerica Bank reduced its stake in Insulet Corporation (NASDAQ:PODD) by 57.0% in the fourth quarter, selling 17,712 shares and holding 13,353 shares v...
Bearish
Rothschild & Co Redburn Downgrades Insulet Corporation (PODD), Cites “Eroding” Product Moats and Distribution
Insulet Corporation (NASDAQ:PODD) has been downgraded to Neutral from Buy by Rothschild & Co Redburn, with a price target reduction from $380 to $220,...
Neutral
Insulet Decries 401(k) Target-Date Fund Suit as Hindsight Attack
Medical device maker Insulet Corp. has requested a federal judge dismiss a proposed class action lawsuit challenging the performance of its 401(k) ret...
Research PODD on:
Ad Space